The tweet was deleted by the author.
But we saved everything 🙂.
Verastem, Inc. announced its plan to host an investor conference call and webcast to present progress and updated preliminary data from its Phase 1/2 TARGET-D 101 study.
The trial focuses on the oral KRAS G12D (ON/OFF) inhibitor VS-7375, assessing both dose escalation and expansion, evaluating the drug as a monotherapy and in combination regimens. The company aims to provide deeper insights into its ongoing research efforts for this promising candidate. Details are being clarified.
Verastem previously secured U.S. FDA Fast Track status for its novel KRAS G12D inhibitor targeting non-small cell lung cancer patients. The company’s development efforts for this candidate have centered on advancing clinical evaluation. Further updates on trial progress and data are expected in the upcoming investor call.